FIELD : medicine; pharmaceuticals.SUBSTANCE : invention refers to pharmaceutical industry, namely to an intranasal composition for treating allergic rhinitis. What is presented is an intranasal composition for treating allergic rhinitis, containing an effective amount of a cationic dendrimer peptide of formula (Arg)8(Lys)4(Lys)2Lys-Ala-Cys-NH2, which is in the basic non-salt form (b-LTP), serving as carrier, and a mixture of siRNA molecules suppressing IL-13 and IL-4 gene expression, represented by sequences GGACCUGCUCUUACAUUUAtt and AAAGAUGUCUGUUACGGUCtt, respectively, wherein the weight ratio of b-LTP to the siRNA molecule mixture is equal to 12.5 : 1, and the number of siRNA molecules in the mixture is the same.EFFECT : disclosed composition is effective in inhibiting expression of a target gene.1 cl, 12 dwg, 4 tbl, 4 ex